Whereas our strategy of utilizing PD-L1-targeted CARs has the advantages of not only eliminating PD-L1-overexpresing cancer cells but also blocking immune checkpoint (PD-1/PD-L1 axis), thereby significantly enhancing T cell antitumor activity. Here, PDCD1 is linked to cancer.